TD52
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H408180

CAS#: 1798328-24-1

Description: TD52 is an erlotinib derivative. TD52 is a putative inhibitor of CIP2A that exhibits potent antitumor efficacy on HCC and TNBC cells. TD52 induces apoptosis through downregulation of CIP2A (Cancerous inhibitor of protein phosphatase 2A) in HCC, NSCLC and TNBC cells.


Chemical Structure

img
TD52
CAS# 1798328-24-1

Theoretical Analysis

Hodoodo Cat#: H408180
Name: TD52
CAS#: 1798328-24-1
Chemical Formula: C24H16N4
Exact Mass: 360.14
Molecular Weight: 360.420
Elemental Analysis: C, 79.98; H, 4.47; N, 15.55

Price and Availability

Size Price Availability Quantity
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 2650 2 Weeks
1g USD 3850 2 Weeks
2g USD 6250 2 Weeks
Bulk inquiry

Synonym: TD52; TD-52; TD 52; erlotinib derivative; erlotinib analogue;

IUPAC/Chemical Name: N2,N3-bis(3-ethynylphenyl)quinoxaline-2,3-diamine

InChi Key: SCUPZFSEJFWQIS-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H16N4/c1-3-17-9-7-11-19(15-17)25-23-24(26-20-12-8-10-18(4-2)16-20)28-22-14-6-5-13-21(22)27-23/h1-2,5-16H,(H,25,27)(H,26,28)

SMILES Code: C#CC1=CC=CC(NC2=NC3=CC=CC=C3N=C2NC4=CC=CC(C#C)=C4)=C1

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Protein phosphatase 2A (PP2A) is a tumor suppressor, which is functionally defective in various cancers. Previously, we found that PP2A activity determined the anticancer effect of bortezomib and erlotinib in hepatocellular carcinoma (HCC) cell

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 360.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Liu CY, Huang TT, Huang CT, Hu MH, Wang DS, Wang WL, Tsai WC, Lee CH, Lau KY, Yang HP, Chen MH, Shiau CW, Tseng LM, Chen KF. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple- negative breast cancer cells. Eur J Cancer. 2017 Feb;72:112-123. doi: 10.1016/j.ejca.2016.11.012. Epub 2016 Dec 24. PMID: 28027514.


2: Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW, Chen KF. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis. 2014 Jul 31;5(7):e1359. doi: 10.1038/cddis.2014.325. PMID: 25077545; PMCID: PMC4123111.


3: Crugliano T, Quaresima B, Gaspari M, Faniello MC, Romeo F, Baudi F, Cuda G, Costanzo F, Venuta S. Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation. Int J Biochem Cell Biol. 2007;39(1):220-6. doi: 10.1016/j.biocel.2006.08.005. Epub 2006 Aug 30. Erratum in: Int J Biochem Cell Biol. 2017 Jul;88:236-237. PMID: 17005433.